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BACKGROUND: Guanidine exchange factor (GEF)-catalysed activation of Rho proteins such as Cdc42 has been shown to have a crucial
role in cellular transformation, malignant progression and invasion. We have previously shown that the HPV16 E6 oncoprotein binds
to the PDZ domain protein Tax-interacting-protein 1 (Tip-1) and we now report identification and functional analysis of a novel
Tip-1 binding GEF.
METHODS: Yeast two-hybrid, in vitro pull-down, site-directed mutagenesis, semiquantitative PCR, co-immunoprecipitation and western
blotting were used to identify/confirm novel Tip-1 binding partners and analyse cellular expression levels. In vitro kinetic analyses of
recombinant proteins, siRNA gene silencing and in cell assays were used to measure Rho protein activation.
RESULTS: Tax-interacting-protein 1 was shown to interact with ARHGEF16 by its carboxyl PDZ binding motif. Levels of ARHGEF16
were increased in transformed and immortalised cells expressing ectopic HPV16 E6 and Cdc42 was co-immunoprecipitated by
ARHGEF16 in the presence of high-risk HPV E6. In vitro kinetic analysis confirmed that recombinant ARHGEF16 activates Cdc42 and
this was increased by the addition of recombinant Tip-1 and E6. Cells expressing HPV16 E6 had higher levels of Cdc42 activation,
which was decreased by siRNA silencing of either Tip-1 or ARHGEF16.
CONCLUSION: These data suggest that HPV16 E6, Tip-1 and ARHGEF16 may cooperate to activate Cdc42 and support a potential link
between the expression of HPV16 E6 and Cdc42 activation.
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The E6 oncoprotein of high-risk HPV type 16 has been shown to be
crucial for the transforming properties of the virus. To further
understand how it may elicit these tumorigenic effects, we have
studied the cellular biological pathways that it targets. As a result
of this, we have previously reported a novel interaction of HPV16
E6 with the class 1 PDZ domain protein Tip-1 (Hampson et al,
2004). Several PDZ domain-containing proteins have been
documented to interact with E6 via its carboxyl terminal PDZ
binding motif. Indeed, this motif has been shown to be essential
for many of its oncogenic properties (Kiyono et al, 1997; Nguyen
et al, 2003; Spanos et al, 2008; Wise-Draper and Wells, 2008).
Interestingly, the downstream consequence of E6 binding is
usually proteasomal degradation of the target PDZ protein, but
we have clearly shown that this is not the case for Tip-1 (Hampson
et al, 2004). Tax-interacting-protein 1 was found to be necessary
for E6-dependent increased cell motility, a hallmark of transfor-
mation, which could be inhibited by the Rho kinase inhibitor
Y27632 (Hampson et al, 2004). As Tip-1 has also been shown to
bind to the carboxyl terminal PDZ binding motif of the human
T-cell leukaemia virus (HTLV1) Tax oncoprotein (Rousset et al,
1998), there is good evidence that Tip-1 may have a role in viral
carcinogenesis.
In support of this, other studies have shown that Tip-1 is
involved in both Rho A and Wnt signalling (Reynaud et al, 2000;
Kanamori et al, 2003), which are two crucial pathways involved in
the neoplastic process (Hampson et al, 2004; Hall and Fujii, 2005;
Lichtig et al, 2010). As Tip-1 has been shown to exist as a dimer in
solution (Aledo et al, 2001), this raises the possibility that
Tip-1 may form a link between E6 and components of these
pathways. This would be consistent with the proposed ability of
viral oncoproteins to promote transcriptional re-programming
by modifying Rho and Wnt protein signalling. Recent work has
also shown that Tip-1 binds to the apoptosis mediator FAS and
undergoes specific conformational rearrangements upon binding
to this and its other ligands (Banerjee et al, 2008). These authors
state that Tip-1 regulates signalling pathways through its PDZ
domain and deregulation of any of these can lead to the
development of cancer. It is also worth noting that they conclude
that identification and characterisation of the protein–protein
interactions of Tip-1 will be critical to understanding how it
regulates cellular dynamics.
As a continuation of our work on E6 and Tip-1 (Hampson et al,
2004), we now describe the results of screening for novel Tip-1
binding partners. This has identified the guanine nucleotide
exchange factor 16 (ARHGEF16; subsequently abbreviated to
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activation of Rho-like GTPases (Rossman et al, 2005), and when
this occurs inappropriately, they can aid malignant transformation
(Fritz and Kaina, 2006). We have previously shown that ectopic
expression of GEF16 can transform NIH3T3 cells (Hampson et al,
2009) and we now show the interaction of Tip-1 with GEF16
combined with preliminary functional characterisation of this
protein.
MATERIALS AND METHODS
Yeast two-hybrid
Tax-interacting-protein 1 was cloned into the yeast vector pEG202
(Origene Technologies, Rockville, MD, USA) and used as bait to
carry out yeast two-hybrid screening and mating assays as
described previously (Hampson et al, 2004).
Expression of GST-Tip fusion protein
The Tip-1 open-reading frame (ORF) was cloned into the pGEX-2T
vector (GE Healthcare, Little Chalfont, Bucks, UK), expressed as a
glutathione S transferase (GST) fusion protein in Escherichia coli
XL1 cells (Stratagene, Amsterdam, the Netherlands) and captured
on glutathione-sepharose (GE Healthcare) according to the
manufacturer’s instructions.
Cloning of GEF16 ORF and construction of GEF16 PDZ
deletion mutant
The 392–1657bp GEF16 ORF from NM_014448 was PCR
amplified with hi-fidelity Taq polymerase (Roche Diagnostics
Ltd, Mannheim, Germany) from a placental cDNA library using
the following primers: GEF16 forward, 50-GCCATGTTCGAGATCC
TCACGT-30; GEF16 reverse, 50-AACCATGCTGGGTCCTTGAGAC-30.
The PCR product was cloned into the pCR4-TOPO vector
(Invitrogen, Paisley, UK) and the sequence fidelity verified.
This was then used as a PCR template for generating wild-type
GEF16: wtGEF16 forward, 50-CTCGGATCCATGTTCGAGATCCTC-30;
wtGEF16 reverse, 50-AACCATGCTGGGTCCTTGAGAC-30;a n dP D Z
deletion mutant GEF16: mutGEF16 forward, 50-CTCGGATCCATG
TTCGAGATCCTC-30; mutGEF16 reverse, 50-CTCGAATTCCTACTCC
ACCCGCAGACG-30.
These products were then cloned into the expression vector
pCITE-4A (Merck Chemicals Ltd, Beeston, Notts, UK) using the
incorporated BamHI and EcoRI restriction sites.
In vitro transcription translation of GEF16 and GEF16 PDZ
deletion mutant
The GEF16 pCITE-4A constructs were used with an in vitro
transcription translation (IVTT) reticulocyte lysate system
(Promega, Southampton, UK) according to the manufacturer’s
instructions to produce S-tagged recombinant GEF16 proteins.
GST pull-down assay
Extract pre-clearing was carried out by incubating 1ml of binding
buffer (1 PBS, 0.1% NP40, 0.5mM DTT, 10% glycerol, 1mM
PMSF and 2mg/ml aprotinin) 40ml of glutathione-sepharose beads
(GE Healthcare) and 80ml of IVTT product at 41C. Following
centrifugation, the pellet was discarded and the IVTT supernatant
divided into two aliquots. Four micrograms of GST control or
GST-Tip-1 protein-bound beads were added to separate aliquots
of pre-cleared supernate and these were incubated at 41C for 2h,
centrifuged as before and the pellet washed 5  with binding
buffer. The beads were then re-suspended in Laemmli buffer (20%
glycerol, 2% SDS, 25mg/ml bromophenol blue, 125mM Tris-HCl
(pH 6.8)) heated to 851C, separated by SDS–PAGE, western blotted
and immunoprobed with anti-GEF16.
Cell culture, stable gene transfection and siRNA silencing
Human HPV-negative C33A cervical cancer cells were cultured
and stably transfected with complete ORFs of E6 from low-risk
HPV6 (C33AT6 E6) and high-risk HPV16 (C33AT16 E6) as
described previously (Hampson et al, 2004; Donne et al, 2007).
Non-transformed human telomerase immortalised keratinocytes
(hTert) cells were routinely cultured as described in Dickson et al
(2000) and were stably transfected with either high-risk (hTertT16
E6) or low-risk E6 (hTertT6 E6) as described previously (Donne
et al, 2009). Both polyclonal and monoclonal cell lines were
derived and expanded in the presence of G418.
Four different siRNAs each for both GEF16 and Tip-1 plus an
‘AllStars’-negative control with no significant off-target homology
were designed by and obtained from Qiagen (West Sussex, UK;
Flexitube). These were transiently transfected into hTertT16 E6
cells using Lipofectamine 2000 according to the manufacturer’s
instructions (Invitrogen), and GEF16 and Tip-1 mRNA down-
regulation was assessed by RT–PCR 48h post-transfection. Using
the identical procedure and culture conditions, hTertT16 E6,
hTertT6 E6 and vector control hTert cells were then transfected in
triplicate with the GEF16 and Tip-1 siRNA oligonucleotides, which
produced the greatest degree of gene silencing and the AllStars-
negative control siRNA. After 48h, protein extracts were prepared
from these cultures for the G-LISACdc42 Activation Assay
Biochem Kit colorimetric Exchange Assay (see ‘In cell-activated
Cdc42 assays’) as per the manufacturer’s instructions. Every data
point was the result off three separate assays from three separately
transfected culture dishes.
RT–PCR
Total cellular RNAs were prepared using the SuperScript III Cells
Direct cDNA Synthesis Kit as recommended by the manufacturer
(Ambion, Cambridgeshire, UK). Total RNAs from tissue samples
were isolated using Trizol Reagent (Invitrogen). All DNaseI-treated
RNAs were then reverse transcribed with random decamers.
Polymerase chain reaction was performed in 20ml of a reaction
mixture containing 2ml of reverse-transcribed product, 10mlo f
2 Bio-Red and 0.1mM of each primer. The specific primer pairs
used were as follows: GAPDH forward, 50-CATTGACCTCAACT
ACATGGT-30, GAPDH reverse, 50-TCGCTCCTGGAAGATGGTGA
T-30; b-actin forward, 50-ATGGGTCAGAAGGATTCCTA-30, b-actin
reverse, 50-ATCACGATGCCAGTGGTAC G-30; Tip-1 forward, 50-CC
GTGGTGCAAAGAGTTGAAA-30, Tip-1 reverse, 50-GTGTGTGACCA
TGGTCATGTC-30; GEF16 forward, 50-GAGTTCTCCTACCAGCAC
AG-30, GEF16 reverse, 50-AGGATCAGGAAGGAGAGCAT-30;a n d
HPV16 E6 forward, 50-AATGTTTCAGGACCCACAGG-30,H P V 1 6E 6
reverse, 50-CATACAGCATATGGATTCCC-30.
The reaction mixture was denatured at 941C for 4min and
amplified between 30 and 33 cycles of 30s denaturation at 941C,
30s annealing at 53–551C and 30s extension at 721C, followed by
a single 5-min extension at 721C.
Competitive RT–PCR
Two microlitres of the RT product was co-amplified with a
constant amount of the competitive template in a final volume of
20ml PCR mixture containing 10mlo f2  Bio-Red (Bioline,
London, UK) and 0.1mM of each primer. The reaction mixture
was amplified as described previously. The PCR products were
separated by 1.5% agarose gel electrophoresis and stained with
ethidium bromide. The intensity of DNA bands was quantified
using the ImageJ 1.38 software.
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The primary antibodies used were as follows: Tip-1, 1:100
(Abnova, Heidelberg, Germany); GEF16, 1:100 (Abnova); RhoA,
1:500 (Pierce Biotechnology, Rockford, IL, USA); Rac1, 1:2000
(Abcam, Cambridge, UK); GAPDH, 1:1500 (Abcam); Cdc42, 1:200
(Cell Biolabs Inc., San Diego, CA, USA); and b-actin 1:1500
westerns and 1:1000 immunostaining (Sigma, Dorset, UK).
Secondary antibodies (DAKO Cytomation, Denmark) were HRP
conjugated for western applications and used at 1:2000.
Immunoprecipitation and western blotting
For immunoprecipitation, cell lysates were prepared with
Cellytic-M Cell Lysis (Sigma-Aldrich, Poole, UK) as recommended
by the manufacturer. Immunocomplexes were precipitated from
1.5ml of prepared cell lysate supernatants (equal concentrations)
using 2mg of anti-GEF16 and 50ml of protein G-sepharose
(Sigma-Aldrich) for 48h at 41C. After two sequential washes using
PBS–0.1% Tween 20, the resulting pellets were heated for 3min
at 851Ci n2  Laemmli buffer (with DTT) and separated by
SDS–PAGE. Western immunoblotting was carried out a described
previously (Hampson et al, 2004).
Rho/GEF exchange assays
Recombinant GEF16 (GenWay Biotech, San Diego, CA, USA),
Tip-1 (made in-house, see previous) and HPV16 E6 (Insight
Biotechnology Limited, Wembley, UK) were used in the RhoGEF
exchange assay kit (Cytoskeleton, Denver, CO, USA). Two-
micromolar concentrations of GEF16, Tip-1 and HPV16 E6
were assayed against RhoA, Rac1 and Cdc42 according to the
manufacturer’s instructions using a Spectra Max Gemini XS
Microplate Spectrofluorometer (Molecular Devices, Sunnyvale,
CA, USA).
In cell-activated Cdc42 assays
Levels of activated Cdc42 were initially assessed in non-
transformed hTertT16 E6 and hTertT6 E6 keratinocytes using
a Cdc42 PAK1 binding activation assay kit (Cell Biolabs Inc.)
according to the manufacturer’s instructions. This was superseded
by the more accurate colorimetric G-LISACdc42 Activation Assay
Biochem Kit (Cytoskeleton), which was used according to the
manufacturer’s instructions. Each data point represents three
separate assays.
RESULTS
Identification and confirmation of GEF16 as a Tip-1
binding protein
To elucidate potential cellular binding partners for Tip-1, a LexA
yeast two-hybrid screen was carried out using Tip-1 as bait. This
identified four clones that were homologous to GEF16, a member
of the Dbl family of Rho GEFs (accession no. BC002681). All the
yeast clones were incomplete and corresponded to nucleotides
1216–1657 at the 30 end of the GEF16 coding sequence. The inter-
action between the GEF16 fragment and Tip-1 was further
confirmed in yeast by a mating assay (Figure 1A). This was not
possible with the full-length 422 amino acid GEF16 protein, as
expression in yeast proved refractory owing to protein instability.
To confirm the GEF16/Tip-1 interaction outside the yeast
system, both full-length wtGEF16 and a deletion mutGEF16 that
lacked the carboxyl terminal PDZ binding motif were produced
by IVTT. The Tip-1 protein was expressed in the bacteria as a
GST fusion and this was used in a GST pull-down assay with the
wtGEF16 and mutGEF16 products (Figure 1B). The GST-Tip-1
protein associated with the wtGEF16 but did not bind to the
mutGEF16 form. The GST control, as expected, did not bind to
either. This indicates that GEF16 most likely interacts with Tip-1
via its carboxyl-terminal PDZ domain.
Expression of HPV16 E6 in transformed cells induces a
moderate upregulation of GEF16 mRNA and protein
As Tip-1 had been previously shown to interact with HPV16 E6
(Hampson et al, 2004), the effects of constitutive ectopic
expression of high-risk E6 proteins on the level of GEF16 mRNA
in C33A cells was investigated by semiquantitative competitive
template PCR (Fandrey and Bunn, 1993). A low-risk type 16
E6-expressing cell line was used as an additional control, as this
lacks the PDZ binding motif found in high-risk E6s. The absence of
this feature in low-risk E6 is thought to contribute to its reduced
tumorigenicity. The results showed that in the presence of high-
risk E6, there was a modest increase in GEF16 mRNA expression
when compared with the parent, vector and low-risk E6-trans-
fected cells (Figure 1C). Anti-GEF16 and Tip-1 antibodies were
then used to immunoprobe a western blot of proteins extracted
from the same cells. This supported the RNA data and confirmed
an increase in the level of GEF16 protein in C33AT16 E6 cells,
whereas Tip-1 expression remained constant across all cells tested
(Figure 1C).
GEF16 co-immunoprecipitates with Tip-1 from MG132-
treated C33AV and C33AT16 E6 cells and differentially
associates with Cdc42
Immunoprecipitation of detectable amounts of GEF16 initially
proved difficult, which suggested that the protein could have a
high rate of turnover. Previous studies have indicated that GEFs
can be unstable (Hayakawa et al, 2005) and proteasomal
degradation has been identified as a regulatory mechanism for
some Rho GEFs such as the proto-oncogene Dbl (Kamynina et al,
2007). Also like Dbl, GEF16 has a stretch of proline, glutamic acid,
serine and threonine residues (PEST sequence) at residues
222–246. These sequences have been implicated in the rapid
turnover of proteins (Rogers et al, 1986). Proline, glutamic acid,
serine and threonine sequences with PEST-FIND scores higher
than þ5 are thought to be the best candidates for degradation
signals (Rechsteiner and Rogers, 1996), and as the GEF16 PEST
has a score of þ13.77, it is very likely to possess this property
(see http://emboss.bioinformatics.nl/cgi-bin/emboss/epestfind). In
light of these observations, it was decided to assess the effects of
pretreating the C33A cultures with the proteasome inhibitor
MG132 to increase the stability of GEF16. Following MG132
treatment, immunoprecipitated GEF16 was found to co-precipitate
with Tip-1 in C33AV and C33AT16 E6 cells, but not low-risk
C33AT6 E6. Further analysis of GEF16 immunoprecipitates showed
no association with the Rho proteins RhoA and Rac (data not
shown), but Cdc42 was detected in immunoprecipitates from
C33AT16 E6 cells. This provides evidence that, in the presence of
high-risk HPV16 E6, GEF16 can associate with Cdc42 (Figure 1D).
GEF16 activates Cdc42 in vitro
The finding that in the presence of high-risk type 16 E6 Cdc42
could co-precipitate with GEF16 (see Figure 1D), coupled with the
presence of a potential Cdc42 binding motif in the GEF16 primary
sequence (see Discussion), suggested that GEF16 could potentially
function as an activator of Cdc42. To address this issue, an in vitro
fluorescent kinetic analysis of Rho protein activation was carried
out. The addition of recombinant GEF16 protein to Cdc42
produced a marked increase in the transfer and exchange of
GTP for GDP bound to Cdc42 at approximately half the rate seen
with the Dbs GEF-positive control (Figure 2A). GEF16 also caused
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(It should be noted that the Dbs-positive control used in the kit is
known by the manufacturers to have reduced activity with Rac1.)
GEF16, Tip-1 and HPV16 E6 cooperate to activate Cdc42
in vitro
The same in vitro fluorescent kinetic assay was used to analyse
GEF16-catalysed Cdc42 activation in the presence of recombinant
Tip-1 and/or HPV16 E6. The addition of the Tip-1 protein plus
GEF16 produced a modest increase in the GTP activation of Cdc42
above that produced by GEF16 alone. The addition of HPV16 E6
plus GEF16 induced a more pronounced activation of Cdc42,
whereas addition of all three recombinant proteins produced the
greatest increase in Cdc42 activation observed (Figure 2B).
Expression of HPV16 E6 is associated with the
upregulation of GEF16 in non-transformed human
keratinocytes (hTert cells)
As C33A cells are a transformed cell line, it was decided to
analyse GEF16 expression in non-transformed E6-transfected
human keratinocyte cultures (hTert cells). Competitive template
RT–PCR analysis showed that GEF16 mRNA was upregulated
in several different monoclonal high-risk E6-expressing hTert cell
lines (hTertT16 E6) when compared with vector control cells
(Figure 3A). Significantly, the level of E6 mRNA detected in each
clone appears to correlate with the level of GEF16 mRNA. Western
blot analysis of protein extracts from a pooled polyclonal
population of these hTert derivative cell lines showed that
upregulated expression of the GEF16 protein was specifically
found associated with cells expressing the T16 E6 protein
(Figure 3B).
hTertT16 E6 cells have higher levels of activated Cdc42
than hTertT6 E6 and vector control hTert cells
As the previous in vitro data suggested that GEF16 could activate
Cdc42, the levels of activated Cdc42 were compared between
E6-expressing and control hTert cells. Western blot analysis of
PAK1-captured, GTP-bound, Cdc42 from cell lysates clearly
showed higher levels of activated Cdc42 are present in hTertT16
E6 cells (Figure 3C) when compared with hTertT6 E6 and vector
control cells. These lysates were also screened for Rac1, but no
detectable signal was seen; thus, the data have not been included
siRNA silencing of GEF16 and Tip-1 markedly reduces
CDc42 activation in hTertT16 E6 cells
To confirm the observed T16 E6-dependent increase in Cdc42
activation shown in Figure 3C, an alternative and more sensitive,
colorimetric ELISA-based Cdc42 activation assay was used to
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Figure 1 Interactions, regulation and stability of GEF16. (A) Yeast
mating assay confirming that Tip-1 binds to short carboxyl terminal GEF16
fragments isolated from the primary Tip-1 yeast two-hybrid screen.
(B) Glutathione transferase pull-down of Tip-1 with IVTT full-length wild-
type and mutant GEF16 (wtGEF16/mutGEF16). The wtGEF16 contains the
PDZ-binding domain ETDV, whereas mutGEF16 has the TDV residues
deleted. Tip-1-GST fusion protein and GST control protein were bound to
glutathione-sepharose beads. These were mixed with equal amounts of the
IVTT wtGEF16 or mutGEF16 proteins, and then washed with binding
buffer. Bound proteins were separated by SDS–PAGE and visualised by
western immunoblotting with anti-GEF16. The GST-Tip-1 protein bound
to the wtGEF16, but did not bind to the mutant form, whereas the GST
control did not bind either product. (C) Competitive template RT–PCR
and western blot analysis of GEF16 and Tip-1 expression in mRNAs and
proteins extracted from C33A, C33AV, C33AT16 E6 and C33AT6 E6
cells. mRNA’s were reverse transcribed and the resulting cDNAs PCR
amplified using primers specific for GAPDH, HPV16 E6, GEF16 and Tip-1
by competitive template PCR. Total proteins were extracted from the
same cells, separated by SDS–PAGE, electroblotted and immunoprobed
with anti-GEF16 and anti-Tip-1. Anti-GAPDH was used as a loading
control. (D) Immunoprecipitation with anti-GEF16 from lysates of C33AV,
C33AT16 E6 and C33AT6 E6 cells treated with 10mM of the selective
proteasome inhibitor MG132 for 4h. When immunoprobed with Tip-1
and Cdc42, it can be seen that Tip-1 is associated with GEF16 in both the
presence and absence of T16 E6. Cdc42 was detected in association with
the GEF16 complex in the presence of HPV type 16 E6, but not in type 6
or vector and parent control cells. (GEF16 has a putative Cdc42 binding site
at amino acids 385–391 (QRTLQKL)).
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of siRNA silencing of Tip-1 or GEF16 on Cdc42 activation. Tax-
interacting-protein 1 siRNA oligo 2 and GEF16 siRNA oligo 2 were
found to be the most effective at silencing their respective mRNAs
and were subsequently used to evaluate the effects of this
procedure on Cdc42 activation (Figure 4). The results verified
that Cdc42 activation was consistently higher in the AllStars siRNA
control oligo-transfected hTertT16 E6 cells than in either AllStars-
transfected hTertT6 E6 or vector cells. Silencing of Tip-1 produced
no significant difference in the extent of Cdc42 activation found in
low-risk E6 hTertT6 E6 or hTert vector cells, whereas silencing of
GEF16 reduced Cdc42 activation in both these cell types. However,
silencing of either Tip-1 or GEF16 in high-risk E6 hTertT16 E6 cells
produced a pronounced reduction of Cdc42 activation when
compared with the AllStars control (Figure 4). None of the siRNAs
used produced any discernible cell death or had any effect on cell
growth characteristics.
DISCUSSION
In this study, we have shown that the HPV16 E6 binding protein
Tip-1 (Hampson et al, 2004) interacts with the Dbl family member
GEF16 via its carboxyl PDZ binding sequence and that ectopic
expression of high-risk, but not low-risk, E6 is associated with a
modest upregulation of GEF16 in both transformed and non-
transformed cells. It is significant that overexpression of GEFs can
promote malignant transformation and progression (Rossman
et al, 2005; Fritz and Kaina, 2006), and we have previously shown
that ectopic expression of GEF16 transforms NIH3T3 cells
(Hampson et al, 2009).
Guanidine exchange factors promote the GTP activation of Rho
GTPase’s by catalysing the exchange of GDP for GTP. The 48-kDa
GEF16 protein reported here is one of the smallest Dbl-related
GEFs containing one src homology 3 domain in addition to the
minimal structural unit (PH/DH domains) and a PDZ binding
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Figure 2 Guanidine exchange factor 16 activates Cdc42 in vitro.( A) Fluorescent kinetic analysis of the ability of recombinant GEF16 to activate Cdc42,
RhoA and Rac1 in vitro. Two micromolar concentrations of GEF16 recombinant protein were added in triplicate to each Rho GTPase being assayed at 4min
after initial readings had been taken with the Rho proteins and assay buffers alone. After the addition of GEF16, it can clearly be seen that there is significant
activation of Cdc42 and to a lesser extent Rac1. (B) Fluorescent kinetic analysis of Cdc42 activation by GEF16 in the presence of high-risk HPV16 E6 and
Tip-1. Different combinations of 2mM concentrations of the recombinant proteins GEF16, Tip-1 and HPV16 E6 were added after 4min of initial readings
being taken with Cdc42 and assay buffers alone. Each combination was carried out in triplicate. It can be seen that Cdc42 activation by GEF16 is enhancedi n
the presence of Tip-1 and E6.
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analysis indicated that GEF16 has a putative Cdc42 binding sequence
QRTLQKL located in its DH domain (Blanke and Jackle, 2006),
which prompted us to investigate its ability to activate this particular
Rho protein.
Initial evidence supporting this hypothesis was provided by
the observation that GEF16 co-immunoprecipitated with both
Tip-1 and Cdc42, although this was only found when high-risk E6
was also present and when cells were pretreated with the
proteasome inhibitor MG132. In the absence of MG132, GEF16
did not co-precipitate with Tip-1 in either control or E6-expressing
cells, which suggests that proteasomal degradation may influence
this interaction. Indeed, MG132 is known to stabilise the
interaction of the Rho-GEF Pbl/ECT2 with the E3 ligase E6AP
(Reiter et al, 2006), and the suggestion that GEF levels may be
regulated by the proteasome has been previously reported by
others. Examples include the Cdc42-specific GEF h-PEM2, which
is subject to proteasomal degradation via the HECT-type E3 ligase
Smurf1 (Yamaguchi et al, 2008) and the Cdc42-specific GEF
FWD1, which is stabilized in the presence of MG132 (Hayakawa
et al, 2005). Indeed, we have shown that the full-length GEF16
protein is unstable in yeast cells and it contains PEST sequences,
which have previously been shown to signal rapid degradation in
yeast (Marchal et al, 1998).
In light of these stability problems, we initially opted to analyse
the ability of recombinant GEF16 to activate Rho proteins using
a kinetic in vitro system. This showed that GEF16 did not activate
Rho A, had a modest ability to activate Rac-1, but showed the
largest activity with Cdc42. These experiments were then extended
to evaluate the effects of adding recombinant GEF16 plus Tip-1,
and GEF16 plus Tip-1 and HPV16 E6 to the Cdc42 assay system,
with the result that the greatest activation was observed when all
three proteins were present. This in vitro assay system has been
used very successfully by others (Guilluy et al, 2010), but, as it is
based on the use of recombinant proteins, we employed two
additional in-cell test systems to establish whether these effects
occurred with native proteins in situ. Both of these in-cell assays
showed that high-risk E6-expressing cells had the greater levels of
Cdc42 activation when compared with vector control or low-risk
T6 E6-expressing cells. Furthermore, since silencing expression of
either Tip-1 or GEF16 produced a highly significant (P¼0.001)
reduction in Cdc42 activation in T16 E6-expressing cells, this
provides clear evidence that these two proteins are involved
with the ability of T16 E6 to upregulate Cdc42 activation in cells.
The observation that silencing Tip-1 has little effect on Cdc42
activation in T6 E6 and vector control cells reinforces the
conclusion that T16 E6 upregulates Cdc42 activation through both
Tip-1 and GEF16.
While the interplay between GEF16, Tip-1 and E6 and the
subsequent alterations in activated Cdc42 levels are clearly
complex and still require further elucidation, the results presented
suggest that GEF16-dependent activation of Cdc42 may be
upregulated by high-risk E6. One potential explanation for these
findings may be the uniqueness of Tip-1 as a PDZ protein in that it
contains only a single class 1 PDZ domain. It is known that the
majority of PDZ proteins contain multiple protein–protein
interaction domains, which act as molecular scaffolds important
for a variety of cellular functions including cell signalling. The
Tip-1 protein is known to form dimers in solution (Aledo et al,
2001) and it has been reported to be a negative regulator of PDZ-
based scaffolding assemblies (Alewine et al, 2006). Therefore, it is
possible that the binding of HPV16 E6 to the Tip-1 PDZ domain
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stably transfected with either HPV16 E6, HPV6 E6 or vector control.
b-Actin was used as a loading control. (C) Western immunoblot analysis
of GTP-activated Cdc42 in HPV16 E6- and HPV6 E6-transfected hTert
cells. hTertT16 E6 cells showed increased levels of activated Cdc42. The
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Figure 4 HPV16 E6-dependent upregulation of Cdc42 activation
depends on the expression of Tip-1 and GEF16. Human telomerase
immortalised keratinocyte T16 E6 cells were transiently transfected with
four different Tip-1 and GEF16 siRNAs (oligos 1–4) plus the AllStars (AS)-
negative control to assess the optimal siRNAs. RT–PCR analysis of mRNA
levels 48h post-transfection showed that oligo 2 was the most effective in
each case. (Tip-1 oligo 2 sequence: 50-CAAGACGGACAAGGGTATTTA-30;
GEF16 oligo 2 sequence: 50-CACGTCGGAGTTCTCCTACCA-30.) For the
main experiment, cells were transiently transfected with Tip-1 oligo 2, GEF16
oligo 2 and the AllStars-negative control, and the colorimetric Cdc42
activation assay carried out 48h later. All cell extracts were adjusted to
0.25mgml
 1 of protein for the assay. AllStars-negative control siRNA-
transfected hTertT16 E6 cells had the highest endogenous level of activated
Cdc42, which was markedly reduced by silencing of Tip-1 or GEF16
expression (Po0.001).
HPV16 E6, Tip-1, ARHGEF16 and Cdc42 activation
AW Oliver et al
329
British Journal of Cancer (2011) 104(2), 324–331 & 2011 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
smay affect its ability to interact with and regulate a signalling
pathway involving GEF16 and Cdc42, resulting in an increase in
activated Cdc42 levels. Indeed, this is supported by the previously
reported interactions of Scrib, bPIX and Cdc42. Scrib is a
multidomain LRR/PDZ scaffold protein, which controls the locali-
sation and activation of Cdc42 via its interaction with bPIX, which
is a Cdc42-activating GEF (Osmani et al, 2006). Furthermore,
it is highly significant that HPV16 E6 has also been shown to
interact with Scrib, yet, unlike Tip-1, this results in its proteasomal
degradation (Nakagawa and Huibregtse, 2000). Thus, it is
hypothesised that the interaction of high-risk E6 with PDZ
proteins, such as Scrib and Tip-1, may cooperate to perturb the
delicate balance of interactions between GEFs (bPIX and/or
GEF16) with Cdc42. This coordinated assault by E6 ultimately
leads to deregulated control of Cdc42 activation.
Our data are not without precedent since it is well known that
other viral oncoproteins can affect Rho protein function. For
example, HTLV1 Tax, which interestingly like HPV high-risk E6
also interacts with Tip-1, has been shown to interact directly with
Rac, Rho and most significantly Cdc42 (Wu et al, 2004). Similarly,
the Epstein–Barr virus LMP1 oncoprotein can promote the
activation of Cdc42 signalling (Eliopoulos and Young, 2001).
Therefore, in summary our data provide evidence that there
are pathways connecting the expression of the high-risk HPV
type 16 E6 protein to enhanced Cdc42 activation and Tip-1 and
GEF16 function as components of this system. The exact nature of
the interplay between these proteins and the precise molecular
mechanisms by which they elicit Cdc42 activation are worthy of
further investigation.
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